ClinicalTrials.gg
RecruitingNCT04747366Updated Feb 10, 2021

Analysis of the Pathophysiology and Pathology of Coronavirus Disease 2019 (COVID-19), Including Chronic Morbidity

An observational study in Covid19, sponsored by Charite University, Berlin, Germany. Recruiting at 11 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-02-10.

Sponsored by Charite University, Berlin, Germany · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Nov 2020; still recruiting 6 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
750
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in COVID-19 by Charite University, Berlin, Germany — 2 open to participants now, 2 under way, none of them phase 3. COVID-19 · Charite University, Berlin, Germany.

Started
2020
with 3 others
Observational
7 of 12
2 open now
Registered
5th of 12
by date

Among the 12 studies in COVID-19 by Charite University, Berlin, Germany, this one is one of 4 that started in 2020, is one of 7 observational ones, and was the 5th registered.

COVID-19

7,996 studies on the registry are indexed under COVID-19; 469 are open to participants now.

Browse COVID-19 studies →

Open to participants now

2 of the 12 studies in COVID-19 by Charite University, Berlin, Germany are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 356 COVID-19 studies recruiting now, 205 (58%) set no upper age limit and 84 (24%) stop at 75 or younger; 90 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in COVID-19 by Charite University, Berlin, Germany, or all of them as a file.
02

Study summary

NAPKON-HAP is the deep phenotyping platform of the National Pandemic Cohort Network (NAPKON) in Germany. NAPKON is a data and biospecimen collection of patients with COVID-19 and is part of the University Medicine Network (NUM) in Germany. The primary objective of the study is to provide a comprehensive collection of data and biosamples for researchers from national consortia and for participation in international research collaborations for studying COVID-19 and future pandemics.

Data is collected from patients with COVID-19 three times per week during their hospitalization and at follow-up visits after hospital discharge 3, 6, 12, 24, and 36 months after symptom onset. Data include epidemiological and demographic parameters, medical history and potential risk factors, documentation of routine medical procedures, and clinical course, including different patterns of organ involvement, quality of care, morbidity, and quality of life. Moreover, extensive serial high-quality bio sampling consisting of various sample types is performed to allow deep molecular, immunological, and virological phenotyping.

Patients not requiring Intensive Care Unit (ICU)/ Intermediate Care (IMC) treatment will receive 7 and patients requiring ICU/IMC treatment will receive 16 full-phenotyping visits including sampling for biobanking. During hospitalisation the planned blood sampling rate in total is 35 ml at each visit. The total amounts and/or sampling dates may differ according to the ethics committee's regulations for different study centers.

At follow-up visits, the clinical assessment includes an update of the medical history and recent medical events from which additional clinical data is collected (i.e. outpatient CT-scans, echocardiography, external laboratory data). Clinical symptoms are recorded and a physical examination will be performed. Vital signs are recorded and routine blood testing and biosampling is continued. Quality of life is measured with patient-reported outcome questionnaires.

Follow-up visits at months 3 and 12 are "deep phenotyping" visits with a comprehensive and detailed set of examinations. In the following visits at months 24 and 36, only examinations with pathologic results from the last deep phenotyping visit at month 12 will be performed.

A shorter follow-up visit to record quality of life, recent medical events and with a reduced number of examinations focusing on cardiorespiratory performance will take place at month 6.

In case of relevant medical events, new medical information or changes in the participant´s health status, an unscheduled visit can take place anytime within the entire study period.

Data collection during follow up includes standardized quality of life assessment including PROMIS® (Patient-Reported Outcomes Measurement Information System). The pulmonary characterization will include body plethysmography, diffusion capacity, respiratory muscles strength measurement, spiroergometry, capillary blood gas analysis and lung imaging studies (low-dose Computed Tomography (CT), Magnetic Resonance Imaging (MRI) of the lung). Cardiological phenotyping includes echocardiography, electrocardiogram (ECG), 24h-ECG, 24h-blood pressure monitoring, stress cardiac MRI and pulse wave analysis. Neurocognitive testing includes brain MRI, electroencephalogram (EEG), somatosensory testing, refractometry (Visit 3 and 12 months), physical activity test, neurocognitive tests, somatosensory phenotyping, taste- and smell-test. Endocrinological phenotyping will incorporate Advanced Glycation Endproducts (AGE) reader, continuous glucose monitoring for 14 days, Air Displacement Plethysmography (ADP) or bioelectrical impedance analysis (BIA).

03

Conditions studied

  • Covid19

Keywords

  • COVID-19
  • coronavirus
  • SARS-CoV-2
  • cohort
  • observational
  • phenotyping
  • NAPKON-HAP
  • NAPKON
  • chronic morbidity
  • pa-covid
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

COVID-19 patients, hospitalised at any of the participating hospitals (see study sites) over the age of 18 years, who are willing and deemed able to participate in the study

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years
  • Willingness to participate in the study (consent to participate by patient or appropriate legal representative) or inclusion via deferred consent
  • Hospitalization at time of enrollment
  • Positive evidence for SARS-CoV-2 infection with PCR (polymerase chain reaction) or initial positive rapid diagnostic test in conjunction with typical clinical symptoms, confirmed by a later positive PCR test.

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate by patient, or appropriate legal representative
  • Any condition that prohibits supplemental blood-sampling beyond routine blood drawing
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
750 participants (estimated)
Target follow-up
36 Months
Patient registry
Yes
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Changes in Patient-reported Quality of life recorded with the help of the European Quality of Life 5 Dimensions 5 Level Version (Eq5d5l) questionnaire

    Health related quality of life after hospital discharge will be assessed with the questionnaire European Quality of Life 5 Dimensions 5 Level Version (Eq5d5l)

    Time frame: day 1 of enrollment in the study, immediately before discharge, 3, 12, 24 and 36 months after symptom onset

  2. Changes in Patient-reported Quality of life recorded with the help of the Short Form Health 36 (Sf36)

    Health related quality of life after hospital discharge will be assessed with the questionnaire Short Form Health 36 (Sf36)

    Time frame: day 1 of enrollment in the study, immediately before discharge, 3, 12, 24 and 36 months after symptom onset

  3. Changes in Patient-reported Quality of life recorded with the help of the Patient-Reported Outcomes Measurement Information System (PROMIS Profile)

    Health related quality of life after hospital discharge will be assessed with the questionnaire Patient-Reported Outcomes Measurement Information System (PROMIS Profile)

    Time frame: day 1 of enrollment in the study, immediately before discharge, 3, 12, 24 and 36 months after symptom onset

  4. Changes in Patient-reported Quality of life recorded with the help of the Neuropathy Questionnaire (Mnsi)

    Health related quality of life after hospital discharge will be assessed with the questionnaire Neuropathy Questionnaire (Mnsi)

    Time frame: day 1 of enrollment in the study, immediately before discharge, 3, 12, 24 and 36 months after symptom onset

  5. Changes in Patient-reported Quality of life recorded with the help of the Trauma Patient Health Questionnaire

    Health related quality of life after hospital discharge will be assessed with the questionnaire Trauma Patient Health Questionnaire

    Time frame: day 1 of enrollment in the study, immediately before discharge, 3, 12, 24 and 36 months after symptom onset

  6. Changes in Patient-reported Quality of life recorded with the help of the PTSD (Post-traumatic stress disorder) Checklist for Diagnostic and Statistical Manual of Mental Disorders 5 (PCL-5).

    Health related quality of life after hospital discharge will be assessed with the PTSD (Post-traumatic stress disorder) Checklist for Diagnostic and Statistical Manual of Mental Disorders 5 (PCL-5). The PTSD Checklist for DSM-5 is a 20-questions self-report measure that assesses the presence and severity of PTSD symptoms.

    Time frame: day 1 of enrollment in the study, immediately before discharge, 3, 12, 24 and 36 months after symptom onset

  7. Changes in Patient-reported Quality of life recorded with the help of the National Eye Institute Visual Function Questionnaire (NEI-VFQ)

    Health related quality of life after hospital discharge will be assessed with the questionnaire National Eye Institute Visual Function Questionnaire (NEI-VFQ)

    Time frame: day 1 of enrollment in the study, immediately before discharge, 3, 12, 24 and 36 months after symptom onset

  8. Changes in Patient-reported Quality of life recorded with the help of the St. George's Respiratory Questionnaire (SGRQ)

    Health related quality of life after hospital discharge will be assessed with the questionnaire St. George's Respiratory Questionnaire (SGRQ)

    Time frame: day 1 of enrollment in the study, immediately before discharge, 3, 12, 24 and 36 months after symptom onset

  9. Changes in neruocognitive testing with Cambridge Neuropsychological Test Automated Battery (CANTAB)

    CANTAB tests can detect changes in neuropsychological performance and include tests of working memory, learning and executive function; visual, verbal and episodic memory; attention, information processing and reaction time; social and emotion recognition, decision making and response control.

    Time frame: at follow-up visits (3 and 12 months after symptom onset and 24 and 36 months after symptom onset (only in case of abnormal results)

  10. Changes in neruocognitive testing with Montreal Cognitive Assessment Test (MOCA)

    This test is a screening procedure to determine cognitive deficits. Central cognitive functions are examined using 11 task complexes. This includes time and spatial orientation, learning and memory, attention, language and language skills, reading, writing, drawing and calculating (test duration approx. 10 minutes).

    Time frame: at follow-up visits (3 and 12 months after symptom onset and 24 and 36 months after symptom onset (only in case of abnormal results)

  11. Changes in blood pressure measured during spiroergometry testing

    Spiroergometry (spirometry while the participant exercises on a bicycle ergometer) is used to evaluate physical performance and fitness. Using spiroergometry blood pressure is measured during the test and compared with normative values.

    Time frame: at follow-up visits (3 and 12 months after symptom onset and 24 and 36 months after symptom onset (only in case of abnormal results)

  12. Changes in sensomotory testing with the questionnaire for peripheral neuropathy (Michigan Neuropathy Screening Instrument, MNSI)

    The MNSI will be used to screen patients for peripheral neuropathy.

    Time frame: at follow-up visits (3 and 12 months after symptom onset and 24 and 36 months after symptom onset (only in case of abnormal results)

  13. Changes in sensomotory testing with the questionnaire (painDETECT-questionnaire, pDQ)

    PainDETECT will be used to screen patients for for neuropathic pain.

    Time frame: at follow-up visits (3 and 12 months after symptom onset and 24 and 36 months after symptom onset (only in case of abnormal results)

  14. Changes in Quantitative sensory testing (QST)

    Quantitative sensory testing (QST) is a method for semiquantative evaluation of somatosensory nervous system disorders, including chronic pain and pain related to various diseases. It essentially determines the sensation and pain thresholds for cold and warm temperatures, and the vibration sensation threshold by stimulating the skin and comparing the results to normative values.

    Time frame: at follow-up visits (3 and 12 months after symptom onset and 24 and 36 months after symptom onset (only in case of abnormal results)

  15. Changes in Point-of-care neurography

    Point-of-care neuography measures nerve conduction using a point-of-care device (DPNcheck, Neurometrix Inc, USA).

    Time frame: at follow-up visits (3 and 12 months after symptom onset and 24 and 36 months after symptom onset (only in case of abnormal results)

  16. Changes in pulmonary function assessed by body plethysmography

    Body plethysmography will yield information on the static and dynamic lung volumes to assess obstructive and restrictive ventilation patterns.

    Time frame: immediately before discharge, at follow-up visits (3, 6 and 12 months after symptom onset and 24 and 36 months after symptom onset (only in case of abnormal results)

  17. Changes in pulmonary function assessed by single breath CO (carbon monoxide) diffusion capacity (DLCO)

    The DLCO test provides a general assessment of the lungs' ability to take up oxygen from the inspiratory air and to release carbon dioxide.

    Time frame: immediately before discharge, at follow-up visits (3, 6 and 12 months after symptom onset and 24 and 36 months after symptom onset (only in case of abnormal results)

  18. Changes in heart rate measured with ECG (Electrocardiogram) during spiroergometry testing

    Spiroergometry (spirometry while the participant exercises on a bicycle ergometer) is used to evaluate physical performance and fitness. ECG is a test, used to monitor the electrical activity of the heart. Standard placement of 12-lead electrodes will be used. The patient´s heart rate will be assessed longitudinally and compared to normative values.

    Time frame: at follow-up visits (3 and 12 months after symptom onset and 24 and 36 months after symptom onset (only in case of abnormal results)

  19. Changes in the oxygen saturation of the blood measured during spiroergometry testing

    Spiroergometry (spirometry while the participant exercises on a bicycle ergometer) is used to evaluate physical performance and fitness. Two blood samples are taken 2 hours apart. The first one is taken before the spiroergometry test and the second one - 120 minutes after the first one. The total concentration of carbon dioxide (ctCO2) of the blood is measured and compared with normative values.

    Time frame: at follow-up visits (3 and 12 months after symptom onset and 24 and 36 months after symptom onset (only in case of abnormal results)

  20. Changes in the total concentration of carbon dioxide (ctCO2) of the blood measured during spiroergometry testing

    Spiroergometry (spirometry while the participant exercises on a bicycle ergometer) is used to evaluate physical performance and fitness. The carbon dioxide content of the blood is measured during the test and compared with normative values.

    Time frame: at follow-up visits (3 and 12 months after symptom onset and 24 and 36 months after symptom onset (only in case of abnormal results)

  21. Changes in the pH value of the blood measured during spiroergometry testing

    Spiroergometry (spirometry while the participant exercises on a bicycle ergometer) is used to evaluate physical performance and fitness. Two blood samples are taken 2 hours apart. The first one is taken before the spiroergometry test and the second one - 120 minutes after the first one. The pH value of the blood is measured and compared with normative values. The pH value describes how acidic or basic the blood is.

    Time frame: at follow-up visits (3 and 12 months after symptom onset and 24 and 36 months after symptom onset (only in case of abnormal results)

  22. Changes in the bicarbonate content of the blood measured during spiroergometry testing

    Spiroergometry (spirometry while the participant exercises on a bicycle ergometer) is used to evaluate physical performance and fitness. Two blood samples are taken 2 hours apart. The first one is taken before the spiroergometry test and the second one - 120 minutes after the first one. The bicarbonate content of the blood is measured and compared with normative values. Bicarbonate is a form of carbon dioxide.

    Time frame: at follow-up visits (3 and 12 months after symptom onset and 24 and 36 months after symptom onset (only in case of abnormal results)

  23. Changes in the blood lactate levels during spiroergometry testing

    Spiroergometry (spirometry while the participant exercises on a bicycle ergometer) is used to evaluate physical performance and fitness. Two blood samples are taken 2 hours apart. The first one is taken before the spiroergometry test and the second one - 120 minutes after the first one. The lactate saturation is measured and compared with normative values.

    Time frame: at follow-up visits (3 and 12 months after symptom onset and 24 and 36 months after symptom onset (only in case of abnormal results)

  24. Changes in the partial pressure of carbon dioxide (pCO2) of the blood measured during spiroergometry testing

    Spiroergometry (spirometry while the participant exercises on a bicycle ergometer) is used to evaluate physical performance and fitness. Two blood samples are taken 2 hours apart. The first one is taken before the spiroergometry test and the second one - 120 minutes after the first one. The partial pressure of carbon dioxide (pCO2) of the blood is measured and compared with normative values.

    Time frame: at follow-up visits (3 and 12 months after symptom onset and 24 and 36 months after symptom onset (only in case of abnormal results)

  25. Changes in heart rhythm type measured with ECG (Electrocardiogram) during spiroergometry testing

    Spiroergometry (spirometry while the participant exercises on a bicycle ergometer) is used to evaluate physical performance and fitness. ECG is a test, used to monitor the electrical activity of the heart. Standard placement of 12-lead electrodes will be used. The patient´s heart rhythm will be assessed. Any abnormalities (too slow, too fast, irregular) will be documented and subsequently clinical consequences are being taken.

    Time frame: at follow-up visits (3 and 12 months after symptom onset and 24 and 36 months after symptom onset (only in case of abnormal results

  26. Changes in time intervals of PQ measured with ECG (Electrocardiogram) during spiroergometry testing

    Spiroergometry (spirometry while the participant exercises on a bicycle ergometer) is used to evaluate physical performance and fitness. ECG is a test, used to monitor the electrical activity of the heart. Standard placement of 12-lead electrodes will be used. The time interval of PQ corresponds to the time interval from the beginning of the P wave to the beginning of the Q wave of the QRS complex. The time interval of PQ gives us information about the time required for the action potential to be transmitted from the atria to the ventricles. The recorded PQ time will be compared to normative values. In case of delayed PQ times, further diagnostic is carried out according to current guidelines.

    Time frame: at follow-up visits (3 and 12 months after symptom onset and 24 and 36 months after symptom onset (only in case of abnormal results)

  27. Changes in time intervals of QRS measured with ECG (Electrocardiogram) during spiroergometry testing

    Spiroergometry (spirometry while the participant exercises on a bicycle ergometer) is used to evaluate physical performance and fitness. ECG is a test, used to monitor the electrical activity of the heart. Standard placement of 12-lead electrodes will be used. The QRS complex is combination of the Q wave, R wave and S wave. The time interval of QRS corresponds to the time needed for ventricular depolarization. The recorded QRS time will be compared to normative values. In case of new diagnosed bundle blocks, further diagnostic is carried out according to current guidelines.

    Time frame: at follow-up visits (3 and 12 months after symptom onset and 24 and 36 months after symptom onset (only in case of abnormal results)

  28. Changes in time intervals of QT measured with ECG (Electrocardiogram) during spiroergometry testing

    Spiroergometry (spirometry while the participant exercises on a bicycle ergometer) is used to evaluate physical performance and fitness. ECG is a test, used to monitor the electrical activity of the heart. Standard placement of 12-lead electrodes will be used. The time interval of QT corresponds to the time interval from the beginning of the Q wave to the end of the T wave. The time interval of QT gives us information about the time required for ventricular depolarisation and repolarisation. The recorded QT time will be compared to normative values. In case of abnormal QT times, further diagnostic is carried out according to current guidelines.

    Time frame: at follow-up visits (3 and 12 months after symptom onset and 24 and 36 months after symptom onset (only in case of abnormal results)

  29. Deviations in the ST segment depicted with the use of ECG (Electrocardiogram) during spiroergometry testing

    Spiroergometry (spirometry while the participant exercises on a bicycle ergometer) is used to evaluate physical performance and fitness. ECG is a test, used to monitor the electrical activity of the heart. Standard placement of 12-lead electrodes will be used. The ST-segment is a section between the end of the S wave and the beginning of the T wave and reflects the depolarized state and initial repolarization of the ventricles. Deviations in the ST segment (elevation or depression) will be documented. In case of ST segment elevation or depression, further diagnostic is carried out according to current guidelines.

    Time frame: at follow-up visits (3 and 12 months after symptom onset and 24 and 36 months after symptom onset (only in case of abnormal results)

Secondary outcomes

  1. Changes in body temperature

    Assessment of the patient´s body temperature will be performed at all visits during the acute phase.

    Time frame: every day during hospitalisation (from date of admission in trial until date of discharge or date of death, assessed up to 100 weeks

  2. Changes in blood pressure

    Assessment of the patient´s blood pressure will be performed at all visits during the acute phase.

    Time frame: every day during hospitalisation (from date of admission in trial until date of discharge or date of death, assessed up to 100 weeks

  3. Changes in heart rate

    Assessment of the patient´s heart rate will be performed at all visits during the acute phase.

    Time frame: every day during hospitalisation (from date of admission in trial until date of discharge or date of death, assessed up to 100 weeks

  4. Changes in breath frequency (respiratory rate)

    Assessment of the patient´s breath frequency (respiratory rate) will be performed at all visits during the acute phase.

    Time frame: every day during hospitalisation (from date of admission in trial until date of discharge or date of death, assessed up to 100 weeks

  5. Changes in peripheral oxygen saturation

    Assessment of the patient´s peripheral oxygen saturation will be performed at all visits during the acute phase.

    Time frame: every day during hospitalisation (from date of admission in trial until date of discharge or date of death, assessed up to 100 weeks

  6. Changes in the clinical score SOFA (sequential organ failure assessment)

    At each study visit on the ICU ward, the SOFA score will be assessed (if provided in the clinical information system).

    Time frame: at primary admission to hospital, upon admission to ICU ward, every Monday, Wednesday and Friday during ICU ward stay, assessed up to 100 weeks

  7. Changes in the clinical score Berlin ARDS (acute respiratory distress syndrome) severity score (if provided)

    At each study visit on the ICU ward, the Berlin ARDS (acute respiratory distress syndrome) severity score will be assessed (if provided in the clinical information system).

    Time frame: every Monday, Wednesday and Friday during ICU ward stay, assessed up to 100 weeks

  8. Changes in the clinical score APACHE (Acute Physiology and Chronic Health Evaluation) Score

    At each study visit on the ICU ward, the APACHE (Acute Physiology and Chronic Health Evaluation) score will be assessed (if provided in the clinical information system).

    Time frame: upon admission to ICU

  9. Changes in the clinical score NEWS (National Early Warning Score)

    At primary admission to hospital NEWS (National Early Warning Score) will be assessed (if provided in the clinical information system).

    Time frame: day 1 of enrollment in the study (day of hospitalization), if available

  10. Changes in the clinical score qSOFA Score (quick sequential organ failure assessment)

    At primary admission to hospital qSOFA Score will be assessed (if provided in the clinical information system).

    Time frame: day 1 of enrollment in the study (day of hospitalization), if available

  11. Changes in the Barthel Index

    The changes in the Barthel Index score will be recorded and evaluated, if provided.

    Time frame: day 1 of enrollment in the study, every Monday, Wednesday and Friday during hospitalisation, (assessed up to 100 weeks?), immediately before discharge, at follow up visits 3, 12, 24 and 36 months after symptom onset

  12. Changes in the Frailty score

    At each study visit during hospitalization (visits are conducted 3 times a week until discharge) the Frailty score will be assessed (if provided in the clinical information system).

    Time frame: day 1 of enrollment in the study, every Monday, Wednesday and Friday during hospitalisation, (assessed up to 100 weeks?), immediately before discharge, at follow up visits 3, 12, 24 and 36 months after symptom onset

  13. Changes in the clinical score Murray Score

    At each study visit on ICU ward the Murray Score will be assessed (if provided in the clinical information system).

    Time frame: every Monday, Wednesday and Friday during ICU ward stay, assessed up to 100 weeks

  14. Changes in the clinical score Glasgow Coma Scale (GCS)

    At each study visit on ICU ward the Glasgow Coma Scale score will be assessed (if provided in the clinical information system).

    Time frame: upon admission to ICU ward, every Monday, Wednesday and Friday ICU ward stay, assessed up to 100 weeks

  15. Changes in the clinical score RASS (Richmond Agitation Sedation Scale)

    At each study visit on ICU ward the RASS (Richmond Agitation Sedation Scale)will be assessed (if provided in the clinical information system).

    Time frame: upon admission to ICU ward, every Monday, Wednesday and Friday ICU ward stay, assessed up to 100 weeks

  16. Changes in the clinical score CAM-ICU (Score Confusion Assessment Method for Intensive Care Unit)

    At each study visit on ICU ward the CAM-ICU (Score Confusion Assessment Method for Intensive Care Unit) score will be assessed (if provided in the clinical information system).

    Time frame: every Monday, Wednesday and Friday during ICU ward stay,assessed up to 100 weeks

  17. Changes in the clinical score SAPSII (Simplified acute physiology Score II)

    At each study visit on ICU ward the SAPSII (Simplified acute physiology Score II) will be assessed (if provided in the clinical information system).

    Time frame: every Monday, Wednesday and Friday during ICU ward stay, assessed up to 100 weeks

  18. Changes in the clinical score NRS (numeric rating scale) pain score

    At each study visit on ICU ward the NRS (numeric rating scale) pain score will be assessed (if provided in the clinical information system).

    Time frame: every Monday, Wednesday and Friday during ICU ward stay, assessed up to 100 weeks

  19. Changes in the clinical score BPS (behavioural pain scale) pain score

    At each study visit on ICU ward the BPS (behavioural pain scale) pain score will be assessed (if provided in the clinical information system).

    Time frame: every Monday, Wednesday and Friday during ICU ward stay, assessed up to 100 weeks

  20. Changes in the clinical score CPOT (Critical Care Pain Observation tool)

    At each study visit on ICU ward the CPOT (Critical Care Pain Observation tool) score will be assessed (if provided in the clinical information system).

    Time frame: every Monday, Wednesday and Friday during ICU ward stay, assessed up to 100 weeks

  21. Changes in the clinical score DDS (Delirium detection score)

    At each study visit on ICU ward the DDS (Delirium detection score) will be assessed (if provided in the clinical information system).

    Time frame: every Monday, Wednesday and Friday during ICU ward stay, assessed up to 100 weeks

  22. Changes in the checked items on the ICDSC (Intensive Care Delirium Screening checklist)

    At each study visit on ICU ward the ICDSC (Intensive Care Delirium Screening checklist) will be assessed (if provided in the clinical information system).

    Time frame: every Monday, Wednesday and Friday during ICU ward stay, assessed up to 100 weeks

  23. Changes in the heart time volume

    Assessment of the patient´s heart time volume will be performed at all visits during their stay in the ICU ward.

    Time frame: every Monday, Wednesday and Friday during ICU ward stay, assessed up to 100 weeks

  24. Changes in the cardiac index

    Assessment of the patient´s cardiac index will be performed at all visits during their stay in the ICU ward.

    Time frame: every Monday, Wednesday and Friday during ICU ward stay, assessed up to 100 weeks

  25. Changes in EVLWI (Extravascular Lung Water Index)

    Assessment of the patient´s Extravascular Lung Water Index measurement will be performed at all visits during their stay in the ICU ward.

    Time frame: every Monday, Wednesday and Friday during ICU ward stay, assessed up to 100 weeks

  26. Changes in Systemic Vascular Resistance Index (SVRI)

    Assessment of the patient´s Systemic Vascular Resistance Index (SVRI) measurement will be performed at all visits during their stay in the ICU ward.

    Time frame: every Monday, Wednesday and Friday during ICU ward stay, assessed up to 100 weeks

  27. Changes in ITBVI (Intrathoracic Blood Volume Index)

    Assessment of the patient´s ITBVI (Intrathoracic Blood Volume Index) measurement will be performed at all visits during their stay in the ICU ward.

    Time frame: every Monday, Wednesday and Friday during ICU ward stay, assessed up to 100 weeks

  28. Changes in the score WHO (World Health Organisation) clinical ordinal scale

    Changes in the patient´s score on the WHO clinical ordinal scale, used to measure illness severity over time will be assessed.

    Time frame: every day during hospital stay (from day of admission until discharge from hospital, assessed up to 100 weeks) and at follow-up visits (3, 12, 24 and 36 months after symptom onset)

  29. Changes in the NYHA (New York Heart Association) score

    The changes in the NYHA (New York Heart Association) score will be recorded and evaluated, if provided.

    Time frame: at deep phenotyping during follow-up visits (3 and 12 months after symptom onset)

  30. Changes in the Post-COVID-19 Functional Status (PCFS) scale

    The changes in the Post-COVID-19 Functional Status (PCFS) scale will be recorded and evaluated, if provided.

    Time frame: at follow-up visits (3, 12, 24 and 36 months after symptom onset)

  31. Changes in the National Institutes of Health Stroke Scale (NIHSS)

    The changes in the National Institutes of Health Stroke Scale (NIHSS) will be recorded and evaluated, if provided.

    Time frame: at deep phenotyping during follow-up visits (3 and 12 months after symptom onset)

  32. Changes in the Katz Index

    The changes in the Katz Index will be recorded and evaluated, if provided.

    Time frame: at follow-up visits (3, 12, 24 and 36 months after symptom onset)

  33. Changes in the Rose Dyspnea Scale

    The changes in the Rose Dyspnea Scale will be recorded and evaluated, if provided.

    Time frame: at deep phenotyping during follow-up visits (3 and 12 months after symptom onset)

07

Study locations

11 of 11 sites recruiting
  • University Medical Center Freiburg Department of Internal Medicine II Department of Infectiology
    Freiburg, Baden-Württemberg 79106, Germany
    Recruiting
  • University Hospital Heidelberg Clinic for Gastroenterology, Infections, Poisoning
    Heidelberg, Baden-Württemberg 69120, Germany
    Recruiting
  • Clinic of the University of Munich Medical Clinic and Polyclinic III
    Munich, Bayern 81377, Germany
    Recruiting
  • University Hospital Frankfurt Medical Clinic II Department of infectiology
    Frankfurt, Hessen 60590, Germany
    Recruiting
  • University Hospital Giessen (+Marburg) Medical Clinic II Pneumology and internal intensive care medicine Infectiology, Gastroenterology, Nephrology
    Gießen, Hessen 35392, Germany
    Recruiting
  • Hanover Medical School Clinic for Pneumology
    Hannover, Niedersachsen 30625, Germany
    Recruiting
  • University Hospital Cologne Internal Medicine I and Hematology and Oncology, Infectiology, additional qualification in Emergency Medicine
    Cologne, Nordrhein-Westfalen 50937, Germany
    Recruiting
  • University Medical Center Schleswig-Holstein (Campus Kiel): Internal medicine, gastroenterology, pneumology, allergology, sleep medicine, emergency medicine, intensive care
    Kiel, Schleswig-Holstein 24105, Germany
    Recruiting
  • University Medical Center Schleswig-Holstein (Campus Lübeck): Internal medicine, gastroenterology, pneumology, allergology, sleep medicine, emergency medicine, intensive care
    Lübeck, Schleswig-Holstein 23538, Germany
    Recruiting
  • University Hospital Jena Department of Internal Medicine IV
    Jena, Thüringen 07747, Germany
    Recruiting
  • Charité University Hospital Berlin Medical Clinic Infectiology and Pneumology CCM/CVK
    Berlin, 13353, Germany
    Recruiting
08

References and documents

Publications

  • Schons M, Pilgram L, Reese JP, Stecher M, Anton G, Appel KS, Bahmer T, Bartschke A, Bellinghausen C, Bernemann I, Brechtel M, Brinkmann F, Brunn C, Dhillon C, Fiessler C, Geisler R, Hamelmann E, Hansch S, Hanses F, Hanss S, Herold S, Heyder R, Hofmann AL, Hopff SM, Horn A, Jakob C, Jiru-Hillmann S, Keil T, Khodamoradi Y, Kohls M, Kraus M, Krefting D, Kunze S, Kurth F, Lieb W, Lippert LJ, Lorbeer R, Lorenz-Depiereux B, Maetzler C, Miljukov O, Nauck M, Pape D, Puntmann V, Reinke L, Rommele C, Rudolph S, Sass J, Schafer C, Schaller J, Schattschneider M, Scheer C, Scherer M, Schmidt S, Schmidt J, Seibel K, Stahl D, Steinbeis F, Stork S, Tauchert M, Tebbe JJ, Thibeault C, Toepfner N, Ungethum K, Vadasz I, Valentin H, Wiedmann S, Zoller T, Nagel E, Krawczak M, von Kalle C, Illig T, Schreiber S, Witzenrath M, Heuschmann P, Vehreschild JJ; NAPKON Research Group. The German National Pandemic Cohort Network (NAPKON): rationale, study design and baseline characteristics. Eur J Epidemiol. 2022 Aug;37(8):849-870. doi: 10.1007/s10654-022-00896-z. Epub 2022 Jul 29. PubMed 35904671 ↗

Individual participant data

Plan to share: No — Given a concrete inquiry and prior consent by the study participants in question, IPD (individual participant data) can be made available on a case by case basis.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2020 (actual). Primary completion is estimated for Nov 2025, 59 months after the start.

Of 1,640 non-industry observational studies under COVID-19, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 30. This study's planned 59 months is above that.

Counting every sponsor, half of 1,774 studies reached it within 13 months; a quarter within 5 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2021
First posted
Feb 10, 2021
StartActual
Nov 6, 2020
Primary completionEst.
Nov 1, 2025
CompletionEst.
Nov 30, 2025
Last update
Feb 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04747366
Collaborators
Network University Medicine NUM, Berlin Institute of Health
Responsible party
Prof. Dr. med. Martin Witzenrath (Prof. Dr. med., Charite University, Berlin, Germany) — Principal investigator
First posted
Feb 10, 2021
Start date
Nov 6, 2020
Primary completion
Nov 1, 2025 (estimated)
Completion
Nov 30, 2025 (estimated)
Last update
Feb 10, 2021

Study contacts

Martin Witzenrath, Prof. Dr. med.
Contact
martin.witzenrath@charite.de
+49 30 450 553 892
Florian Kurth, PD Dr.
Contact
florian.kurth@charite.de
Martin Witzenrath, Prof. Dr. med.
principal investigator · Charite University Hospital Berlin

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion